Alliance Pharma Share News (APH)

DIRECTOR DEALINGS: Wife Of Alliance Pharma Executive Sells 300,000 Shares

LONDON (Alliance News) - Alliance Pharma PLC Monday said Lynette Booley, wife of Executive Director Anthony Booley, sold 300,000 shares at 33.5 pence each on Friday. Following this transaction, Anthony Booley has a beneficial interest in 4.3 million shares, representing approximately 1.63%

UPDATE: UK BROKER RATING CHANGES: Deutsche Bank Cuts View On Mining Sector

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
BERENBERG RAISES ASTRAZENECA PRICE TARGET TO 3600 (3430) PENCE - 'HOLD'
----------
MORGAN STANLEY RAISES ASTRAZENE

UK BROKER RATING CHANGES: Deutsche Bank Cuts View On Miners

LONDON (Alliance News) - The following UK shares received analyst recommendations Wednesday morning:
----------
FTSE 100
----------
BERENBERG RAISES ASTRAZENECA PRICE TARGET TO 3600 (3430) PENCE - 'HOLD'
----------
MORGAN STANLEY RAISES ASTRAZENE

Alliance Pharma hits annual target and acquires Bayer product - UPDATE

Better sales from its dermatology and post-abdominal surgery treatment products helped AIM drug company Alliance Pharma hit profit expectations for 2013. In a statement before the AIM-listed company enters its close period, Alliance said annual turnover was expected to hit £45.5m, up marginally fr

Alliance Pharma Has Acquisition War Chest After Financing Deal

Alliance Pharma To List More Shares After Loan Stock Conversion

Alliance Pharma gets product mix right for first half profits

Thanks to lower costs and slow and steady sales growth, drug investor Alliance Pharma made a strong start to the year. With sales up 4% to £22.8m in line with expectations, profits before tax 29% higher at £6.8m were ahead of analyst forecasts thanks to a product mix producing lower costs. Chairma

Alliance Pharma Lifted By Cyclical Toxicology Product; Dividend Up 10%

Wednesday broker round-up UPDATE

Aggreko: UBS cuts target price from 1975p to 1850p downgrading from buy to neutral. JP Morgan revises target price from 1870p to 1800p and retains a neutral rating. Alliance Pharma: Investec shifts target price from 35.20p to 35.80p, while downgrading from add to hold. Associated British Food: UBS

Friday tips round-up: Severn Trent, Johnson Matthey, Alliance Pharma

Severn Trent is one of a dwindling group of remaining publicly listed water companies. For The Times´s Tempus the bidding for the water firm is not yet over. While the newspaper column does not think that its suitors will pay the 23 pounds which some institutional investors expect, it does expect a

Thursday broker round-up UPDATE

Aggreko: Goldman Sachs cuts target price from 2425p to 2125p, while retaining its buy recommendation. Alliance Pharma: FinnCap shifts target price from 35p to 38.50p and stays with its hold recommendation. APR Energy: Goldman Sachs reduces target price from 990p to 945p keeping a buy recommendatio

Hargreaves Lansdown Marketing Director reduces stake by 200,000 shares

In a deal announced after Thursday's close, Ian Hunter, the Investment Marketing Director of financial services provider Hargreaves Lansdown, has pocketed £1.51m after reducing his stake in the company by 200,000 shares. Hunter, who has held a position of the board since 2009, traded in the shares

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Small caps round-up: Angel Biotech, Alliance Pharma, Fastjet

Angel Biotech has seen a continuation of the 'very difficult' market conditions since mid-September, with funding constraints of clients forcing delays and changed priorities with a number of potential customers. However, the group is currently seeing an upturn in the volume of enquiries and bids, e

Friday broker round-up - UPDATE

Aggreko: Jefferies keeps buy rating and 2,800p target; Seymour Pierce keeps buy rating and 2,500p target; Panmure Gordon cuts target from 2,228p to 2,159p, hold rating unchanged. Alliance Pharma: umps upgrades to buy, target lifted from 32p to 37p. Avacta: Panmure Gordon keeps buy rating and 1.75p